Insight

Aradhana Kasimsetty: Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer

Photo collage of Aradhana Kasimsetty and Denise Sabatino

Apr 21, 2024, 18:27

Aradhana Kasimsetty: Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer

Aradhana Kasimsetty, , shared on LinkedIn:

“With the recent FDA guidances on gene therapy products, risk management and concerns of vector-derived malignancies are at the forefront of clinical development.

As part of the special issue “Liver Directed Adeno‐Associated Virus Gene Therapy”, Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer and how integration site monitoring synergizes with routine patient care after liver-directed gene therapy.

Integration and the risk of liver cancer—Is there a real risk?”

Additional information.
Source: Aradhana Kasimsetty/LinkedIn

Adeno‐Associated Virus Gene Therapy Aradhana Kasimsetty cancer Denise Sabatino FDA gene therapy liver cancer OncoDaily Oncology Perelman School of Medicine

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage